Literature DB >> 22359097

Decreasing radiation therapy utilization in adult patients with glioblastoma multiforme: a population-based analysis.

Gary V Walker1, Jing Li, Anita Mahajan, Mary Frances McAleer, John F de Groot, Syed S Azeem, Paul D Brown.   

Abstract

BACKGROUND: The purpose of this study was to assess what factors influence radiation therapy (RT) utilization in patients with glioblastoma and to ascertain how patterns of care have changed over time.
METHODS: A total of 9103 patients with supratentorial glioblastoma in the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2006 were analyzed. Demographic information was obtained, including age, sex, race, year of diagnosis, and marital status. Treatment characteristics included receipt of RT and surgical resection.
RESULTS: In total, 76.8% of patients received RT, whereas 78% received resection. Patients of male sex, who were currently married, who were <65 years old, and who underwent resection were more likely to receive RT. The average annual percentage change in RT utilization in the years 1990-2006 was -0.41% (95% confidence interval [CI], -0.23 to -0.58), whereas for resection it was 0.26% (95% CI, 0.03 to 0.50). This equates to a 6.5% decrease in RT utilization and a 4.2% increase in resection during this time period. Patients treated with RT had a 2-year overall survival of 11.4%, compared with 5.2% in those not treated with RT (P < .00001). Multivariate analysis showed that younger age (continuous; odds ratio [OR], 0.97; P < .0001), marital status (OR, 1.62; P < .0001), surgical resection (OR, 1.72; P < .0001), and year of diagnosis 1998-2006 compared with 1990-1997 (OR, 0.82; P < .0001) were associated with RT utilization, whereas sex, lesion size, and race were not.
CONCLUSIONS: SEER data show a decreasing utilization of RT in patients with glioblastoma from 1990 to 2006. Patients who were older, who were unmarried, and who underwent biopsy only were less likely to receive RT.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22359097     DOI: 10.1002/cncr.27439

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma.

Authors:  Maryam Shabihkhani; Donatello Telesca; Masoud Movassaghi; Yalda B Naeini; Kourosh M Naeini; Seyed Amin Hojat; Diviya Gupta; Gregory M Lucey; Michael Ontiveros; Michael W Wang; Lauren S Hanna; Desiree E Sanchez; Sergey Mareninov; Negar Khanlou; Harry V Vinters; Marvin Bergsneider; Phioanh Leia Nghiemphu; Albert Lai; Linda M Liau; Timothy F Cloughesy; William H Yong
Journal:  J Neurooncol       Date:  2017-02-04       Impact factor: 4.130

2.  Improved survival for elderly married glioblastoma patients : Better treatment delivery, less toxicity, and fewer disease complications.

Authors:  Florian Putz; Tobias Putz; Nicole Goerig; Stefan Knippen; Thomas Gryc; Ilker Eyüpoglu; Karl Rössler; Sabine Semrau; Sebastian Lettmaier; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2016-09-14       Impact factor: 3.621

3.  Temozolomide use in adult patients with gliosarcoma: an evolving clinical practice.

Authors:  Gary V Walker; Mark R Gilbert; Sujit S Prabhu; Paul D Brown; Mary Frances McAleer
Journal:  J Neurooncol       Date:  2012-12-25       Impact factor: 4.130

4.  Treatment Patterns and Outcomes Among Elderly Glioblastoma Patients in Riyadh, Saudi Arabia.

Authors:  Amal Marie; Ahmed Maklad; Abdullah AlTwairgi; Moemen Aly; Ashraf Elyamany; Wafaa AlShaqweer; Mohamed Senosy; Ali Balbaid
Journal:  Onco Targets Ther       Date:  2022-02-02       Impact factor: 4.147

Review 5.  Treatment options and outcomes for glioblastoma in the elderly patient.

Authors:  Nils D Arvold; David A Reardon
Journal:  Clin Interv Aging       Date:  2014-02-21       Impact factor: 4.458

6.  The radiosensitivity index predicts for overall survival in glioblastoma.

Authors:  Kamran A Ahmed; Prakash Chinnaiyan; William J Fulp; Steven Eschrich; Javier F Torres-Roca; Jimmy J Caudell
Journal:  Oncotarget       Date:  2015-10-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.